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10 ABSTRACT
Introduction: Inflammatory bowel diseases (IBD) require long-term administration of immunomodula-
tory treatments to maintain disease remission. Due to the high worldwide prevalence of hepatitis B
(HBV) or C (HCV) virus infections, presence of concurrent hepatitis can be a relevant clinical issue to
manage when treating IBD.
15 Areas covered: The paper summarizes epidemiological data about IBD and HBV/HCV infection and
reviews current knowledge about the natural history of HBV and HCV in the IBD setting, concentrating
on risk of hepatitis reactivation during immunosuppressive treatment. Most updated recommendations
for management of HBV and HCV infections in IBD patients are discussed.
Expert commentary: The development of new drugs for IBD with different molecular targets and the
20 availability of potent and efficacious antiviral drugs for HBV and HCV will simplify management of
hepatitis infection in IBD patients in the near future.
ARTICLE HISTORY
Received 7 August 2016
Accepted 6 October 2016
Published online xx xxx xxxx
KEYWORDS
Anti-TNF; HBV; HCV;
immunosuppressive
treatment; inflammatory
bowel diseases; viral
hepatitis
1. Introduction
The management of patients with chronic viral hepatitis or
25 inflammatory bowel diseases (IBD) has been revolutionized in
the last years by the introduction of highly effective treat-
ments. The availability of potent antivirals against hepatitis B
virus (HBV) and hepatitis C virus (HCV), as well as the intro-
duction of anti-TNF biological drugs, has improved patients’
30 survival and quality of life. Although viral hepatitis and IBD do
not share any common pathological pathway and thus are
usually not clinically associated, it is not uncommon to find
patients who are both chronically infected with HBV or HCV
and have IBD, given the relatively high prevalence of these
35 diseases. As shown by several studies across Europe, the pre-
valence of patients with coexisting viral hepatitis and IBD
usually follows the epidemiology of viral hepatitis in the single
country [1,2]. From a clinical standpoint, the management of
these patients is challenging due to many reasons: drugs used
40 in the treatment of IBD may result in liver toxicity, thus leading
to worsening of the coexisting liver disease; immunosuppres-
sive regimens used to treat IBD may lead to viral reactivation
which can progress to liver failure in selected cases; moreover,
drug–drug interactions (DDIs) between therapies administered
45 for viral hepatitis or IBD may lead to reduced response rates or
unexpected adverse events. In this review, we will analyze the
most recent literature on these topics to determine the opti-
mal management of viral hepatitis in patients with IBD in
Europe.
502. Epidemiology of HBV and HCV
Prevalence of chronic Hepatitis B in Europe ranges from 0.4–0.5%
reported in Northern Europe and countries such as Spain to 3.4%
and 5.6% reported in Greece and Romania, respectively, to more
than 8% in the strict European neighbo rhood like Turkey [3,4].
55Eastern countries, including Eastern Europe, Russia, and Eastern
Asia represent areas with intermediate–high HBV endemicity,
with HBV prevalence ranging from 2% to more than 8% in
South east Asian countries. Although new incident cases are
steadily declining due to the implementation of a vaccination
60policy for HBV in most European countries, the increase in migra-
tion from areas of high endemicity that Europe is witnessing
might significantly alter the epidemiology profile of HBV in
Europe in the next decade. The impact of migration can already
be witnessed in countries with a historically high prevalence,
65such as Italy, where  two different populations of chronically
 HBV-infected patients exist. The first consists mostly of men in
their 50–60s that were infected locally decades ago, and usually
present with mild moderate liver disease. The second group is
mostly constituted by migrants who are of younger age, are
70often coinfected with HDV or HIV and have features of advanced
disease [5]. This second group of HBV patients is often undiag-
nosed, or not linked to specialist care.
Chronic infection with HCV is found in 0.1–3.2% of the
European population, once again with significant heterogene-
75ity between European countries. There is a north–south
gradient with an estimated prevalence in Northern Europe of
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around 0.3% increasing to 1–2% in Italy and Greece. Chronic
HCV is also highly prevalent in Eastern Europe (Romania
reporting 3.2% prevalence) and in the Southern Italian regions,
80 where HCV prevalence is more than 6–8% [3,6–8]. Most HCV
cases in Europe can be traced to two global pandemias: the
first one occurred from 1940 to 1970 and is related to iatro-
genic transmission of the virus through contaminated blood
products, while the second one followed the spreading of
85 intravenous-drug use in the 1970 s and 1980 s [9]. The local
epidemiology of HCV in one country can thus be estimated by
understanding which pandemia influenced the spread of HCV
locally. In Southern Europe, where most HCV cases were
infected due to iatrogenic spread, patients are older and the
90 burden of HCV has already peaked and is now declining due
to death for liver or not  liver-related causes of the original
cohort of patients. In Northern Europe on the other hand
where nearly 75% of HCV cases can be found in people who
inject drugs (PWID), patients are younger and the burden of
95 the disease is still increasing and is expected to peak in the
next 10–15 years [10]. Given that HBV, HCV, and IBD do not
share common disease pathways, and since the risk of acquir-
ing viral hepatitis through iatrogenic procedures is now extre-
mely low, there is no specific reason to suspect that patients
100 with IBD should more often be chronically infected with HBV
or HCV. Supporting this theory are data gathered throughout
Europe that demonstrate that the prevalence of chronic HBV
or HCV infection in IBD patients mimics what reported in the
general population of the specific country [1,2,11–15]. Studies
105 concerning HBV and HCV prevalence in IBD patients are sum-
marized in Table 1.
Many studies have underlined the low prevalence of anti-
HBV vaccination in IBD patients, ranging from 12% reported
by a Spanish multicenter study to 23% in a single-center
110 Italian experience [1,14]. This results both from little awareness
and implementation of immunization policies by physicians
and also from reduced efficacy of anti-HBV vaccination in
immunocompromised patients (see paragraph 4). However,
the development of nationwide HBV vaccination programs in
115 many European countries is expected to raise prevalence of
HBV vaccination in the general population in the near future,
starting from younger generations.
2.1. Epidemiology of IBD
In close analogy with other immune-mediated diseases, IBD
120 incidence is characterized by a north–south and a urban–rural
gradient [16]; additionally, most epidemiological studies have
reported a higher prevalence of IBD in Western with respect to
Eastern countries. Even if the reasons underlying these geo-
graphical trends have not been elucidated, differences in diet,
125sun exposure, and intestinal microbiome have been impli-
cated [17]. Notably, of the 5 million people worldwide affected
by IBD, it is estimated that 1.5 million reside in the United
States and nearly 3 million in Europe [18], where a west–east
gradient has been reported. However, these data should be
130interpreted with caution as they are limited by the paucity of
high-quality population-based studies available in Eastern and
developing countries. Recent studies estimate an annual
ulcerative colitis (UC) incidence ranging from 0 to 19.2 per
100,000 and from 0.6 to 24.3 per 100,000/year in North
135America and Europe, accounting for a prevalence of 37.5–
248.6 per 100,000 and 4.9–505 per 100,000, respectively [19].
Similar incidence rates have been reported AQ2for Crohn’s disease
(CD) (0–20.2 per 100,000/year in North America and 0.3–12.7
per 100,000 in Europe). On the contrary, the recent Asia-Pacific
140Crohn’s and Colitis Epidemiology Study (ACCES), including
China, Hong Kong, Indonesia, Sri Lanka, Macau, Malaysia,
Singapore, and Thailand, reported an average incidence of
IBD in Asia of 1.4 per 100,000 individuals, significantly lower
than the incidence in the nearby Australia (24 per 100,000)
145[20]. A more in-depth analysis of disease subtypes led to the
demonstration that UC is more prevalent than CD in Europe
and in Asia, while the opposite is true for Australia; in the
United States, CD and UC are equally distributed [19]. Only
scant data are available regarding IBD diffusion in other coun-
150tries: in Brazil, an incidence of 4.5 and 3.5 per 100,000 indivi-
duals has been reported for UC and CD, respectively [21]; in
the Punjab state of Northern India, an incidence of 6 per
100,000 has been reported for UC [22].
As IBD prevalence is due to rise in the next years due to
155compounding prevalence (i.e. an exponential rise in preva-
lence due to cumulative addition of incident cases in a chronic
disease that has a young age of onset and low mortality),
several studies suggest that IBD incidence also is on the rise
in both Western and Eastern countries. No clear explanations
160have been provided for the rising incidence of IBD worldwide,
even if it has been hypothesized that it may result from a
combination of advances in health care infrastructure (e.g.
easier and quicker access to endoscopy) and environmental
factors. The latter explanation is further corroborated by the
165significantly increased IBD incidence in migrants with respect
to that observed in their countries of origin [23].
Table 1. Prevalence of viral hepatitis in IBD patients.
Study Year IBD type Patients HBsAg % Anti-HBc % Anti-HCV %
 Biancone et al. [11]
Multicentre, Italy
2001 CD/UC 332/162 2.1/0.64 11/11.5 7.4/0.6
 Esteve et al. [12]
Multicentre, Spain
2004 CD 80 3.7 7.5 1.2
Tolentino et al. [13]
Single-center, Brazil
2008 CD + UC 176 2.3 17 –
 Loras et al. [14]
REPENTINA-1 Spain
2009 CD/UC 1128/928 0.6/0.8 7.1/8 2.3/1.3
 Chevaux et al. [15]
Single-center, France
2010 CD/UC 252/63 0.79/1.59 2.8/1.6 0.79/1.59
Weightened prevalence 3121 1% 8.1% 3.3%
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3. Clinical challenges: interplay between IBD and
viral hepatitis
The natural history of HBV or HCV infection in the setting of
170 IBD is poorly understood and studied, due to the scarcity of
prospective data and presence of many confounding factors:
indeed, exposure to multiple and sequential immunosuppres-
sive treatments for IBD management could theoretically deter-
mine a more rapid progression of HBV or HCV-related liver
175 disease. On the other hand, presence of a immune-mediated
disease like IBD was considered a relative contraindication to
Interferon (IFN)-based treatment of HBV or HCV in the past,
due to the increased risk of IBD exacerbation, so that IBD
patients were less likely to receive antiviral treatment for
180 HCV in the IFN-based era, thus providing a potential bias in
determining a worse outcome of IBD-HCV patients with
respect to the HCV general population. In the HBV setting,
administration of nucleoside or nucleotide analog s (NUCs), to
treat HBV-related chronic hepatitis or prevent HBV reactivation
185 during immunosuppressive therapy, impairs the possibility to
evaluate the natural history of HBV infection in IBD patients.
The largest patient series providing information about long-
term outcome of liver disease in IBD patients comes from a
Spanish multicenter study (REPENTINA study), including 25
190  HBsAg-positive and 74 HCV-infected patients with known diag-
nosis of IBD and available data during a follow-up of more than
20 years: 4 out of 25 HBsAg-positive patients (16%) developed
liver cirrhosis after a mean of 13.5 ± 4.2 years from the diagnosis
of HBV infection, while the corresponding figures for HCVwere 8/
195 74 (10.8%) after a median of 16.7 ± 4.8 years. No association was
reported between cirrhosis development and prolonged or com-
bined immunosuppressive treatment [24], suggesting that pro-
gression of liver disease in IBD patients seems to be similar to
what reported in the general HBV or HCV population and that
200 administration of immunosuppressants does not result in accel-
erated liver disease progression as reported instead for immuno-
suppressive therapy in the organ transplantation setting.
It is now well known that immunosuppressive treatment
confers an increased risk of viral reactivation in HBV infection:
205 this is due to the fact that humoral and, especially, cellular
immune responses are crucial for the control of HBV replica-
tion [25]. Indeed, tumor necrosis factor-α (TNF-α) and IFN-γ,
targeted by immunosuppressants and anti-TNF drugs are key
cytokines involved in HBV clearance from infected hepato-
210 cytes, through elimination of cytosolic HBV replicative inter-
mediates and nuclear covalently close circular DNA (cccDNA).
Enhanced viral replication during the administration of immu-
nosuppressive regimens results in hepatitis reactivation after
the discontinuation of immunosuppressive drugs when
215 immune reconstitution occurs and infected hepatocytes are
targeted by the immune system. As a consequence, hepatitis
reactivation typically occurs after immunosuppressive treat-
ment is withdrawn [26].
Current evidence suggests that risk of HBV reactivation is
220 proportionally linked to the level of immunosuppression
achieved. ‘Conventional’ drugs such as corticosteroids and
azathioprine (AZA) seem to provide milder immunosuppressive
levels and, consequently, a low risk of HBV reactivation has been
reported. However, while an Italian group did not observe any
225reactivation in four HBsAg-positive patients treated with AZA or
steroids across a 1-year follow-up period [11], some HBV reacti-
vations during steroids and AZA treatment are described, result-
ing in fulminant hepatitis and hepatic failure in few cases
[24,27,28]. In the REPENTINA trial, 9 out of 25 (36%)  HBsAg-
230positive IBD patients receiving different immunosuppressive
regimens experienced HBV reactivation, defined as a 1.5– 2-fold
increase in aminotransferase values from baseline and HBV-DNA
reappearance or increase > 2000 IU/ml. Seven out of these nine
cases occurred in patients treated with corticosteroids and/or
235AZA, most cases during combined administration of corticoster-
oids + AZA, while only two patients experienced HBV reactiva-
tion during steroid monotherapy. Six patients were treated with
the NUC Lamivudine to manage HBV reactivation ; however, in
 three patients, liver transplantation was required due to devel-
240opment of hepatic failure. Three patients did not receive antiviral
treatment and HBV reactivation was managed by tapering the
immunosuppressive treatment. Combined immunosuppressive
regimen was confirmed at the multivariate analysis as the stron-
gest risk factor for HBV reactivation ( OR 8.75, 95% CI 1.16–
24565.66 ) [24].
Reinforcing the concept that AQ3more pronounced immuno-
suppression is associated with higher risk of reactivation is the
growing number of case reports of HBV reactivations during
treatment with anti-TNF drugs, that are characterized by dif-
250ferent mechanism of action with respect to standard immu-
nosuppressants [12,29–34]. Taken together, these case reports
account for  eight HBV reactivations occurring during
Infliximab (IFX)-based treatment: CD was the underlying IBD
in all cases, and the vast majority of patients received com-
255bined treatment with almost another immunosuppressive
drug (corticosteroids and/or AZA). Timing for reactivation ran-
ged from 1 IFX infusion to 24-month treatment course; sever-
ity of HBV reactivation varied from mild aminotransferase
increase to fulminant hepatitis and two out of eight patients
260died. Six patients received anti-HBV therapy with Lamivudine
during viral reactivation, with four patients successfully reco-
vering following antiviral therapy. In the REPENTINA study, IFX
was the anti-TNF involved in three out the nine HBV reactiva-
tions reported, always in combination regimens with steroids
265and/or AZA: two patients were treated with Lamivudine or the
second-generation NUC Adefovir, which were not able to pre-
vent liver failure and death in one case. The only patient who
did not received anti-HBV treatment recovered after disconti-
nuation of immunosuppressants and surgical bowel resec-
270tion [24].
Another key factor differentiating the risk of HBV reactiva-
tion in the IBD setting from patients receiving immunosup-
pressants for oncologic diseases is the prolonged treatment
duration ; while chemotherapy is administered for short and
275repeated cycles, treatment of IBD patients is prolonged long 
term, although the level of immunosuppression achieved is
lower than classical chemotherapy. The importance of pro-
longed treatment duration has been confirmed by a retro-
spective Korean study, evaluating 134  HBsAg-positive IBD
280patients treated with different kinds of immunosuppressive
treatments (corticosteroids, IFX, and AZA/6-mercaptopurine):
liver dysfunction occurred in 23 patients (17.2%), prolonged
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(>3 months) immunosuppression representing the strongest
risk factor [35].
285 No cases of HBV reactivation with the other anti-TNF drug
Adalimumab (ADA) in IBD patients have been described till now;
however, HBV reactivations are reported in two patients receiv-
ing ADA as anti-TNF treatment for rheumatological diseases,
resulting in severe hepatic failure and death in one case [36–38].
290 In HBsAg-negative anti- HBc-positive patients, that is, patients
with previous HBV contact, risk of HBV reactivation due to
immunosuppressive treatment seems negligible. Literature
reports only four cases of HBV reactivation in anti- HBc-positive
patients receiving anti-TNF treatment, efficiently managed
295 through anti-HBV treatment administration, except for one
patient developing severe hepatic failure [38–41]. On the
other hand, many case series in the rheumatological setting
confirm absence of HBV reactivation in more than 200 HBsAg-
negative patients receiving different anti-TNF drugs [42].
300 Concerning HCV-infected patients, administration of immu-
nosuppressive treatment was historically thought to worsen the
outcome of liver disease, this hypothesis being reinforced by the
accelerated fibrosis progression in HCV patients receiving immu-
nosuppressants for liver transplantation and by the observation
305 that steroid treatment could increase viral load [43,44]. However,
these concepts have not been confirmed in the setting of IBD
patients, where immunosuppression does not seem to signifi-
cantly affect liver disease progression [24]. Conversely, modula-
tion of TNF-α pathways has been claimed even beneficial in HCV
310 patients, as TNF-α is involved in liver inflammation and hepato-
cyte apoptosis, and upregulation of TNF pathways was thought
to affect non response to IFN-based treatments [45,46]. Indeed, a
randomized controlled trial in HCV-infected patients, investigat-
ing the role of the anti-TNF Etanercept in combination with IFN
315 and Ribavirin for anti-HCV treatment, showed a significant reduc-
tion in aminotransferase values and a higher HCV-RNA decline in
the Etanercept arm [47].
Few data exist about outcome of immunosuppressive therapy
for IBD in HCV patients, however presence of HCV infection does
320 not seem to represent a major concern in treatment of IBD
patients: in the REPENTINA study, 8/51 (16%) HCV patients treated
for IBD developed a 1.5–2-fold increase in aminotransferase values
or a significant increase inHCVviral load, however these alterations
were not clinically relevant [24]. Similarly, Morisco and colleagues
325 reported mild elevation of transaminases and viral load in 1 out of
10 HCV patients treated for IBD [41] and twomore reports about 4
CD patients treated with IFX showed no significant change in liver
function tests and serum HCV-RNA during a maximum of
12 months treatment course [48,49]. Apart from IBD patients,
330 many reports concerning anti-TNF treatment for rheumatologic
diseases show no significant safety concern in HCV patients in
more than 153 patients [42,50]. Finally, methotrexate and AZA
have also been shown safe in HCV-infected patients, both in treat-
ing rheumatologic diseases and in liver transplanted patients [51].
335 4. Treatment of viral hepatitis and hepatitis
reactivation
Current guidelines from the European Crohn’s and Colitis
Organisation (ECCO) recommend testing for HBV and HCV
markers before starting immunosuppressive treatment for
340IBD. Concerning HBV, complete serology is required to deter-
mine the patient’s virological status: in detail, assessment of
HBsAg, anti-HBs, anti-HBc is recommended and, in  HBsAg-
positive patients, HBeAg, anti-HBe, and HBV-DNA quantifica-
tion are required. These tests allow to define the HBV profile
345(active carrier, inactive carrier, or anti-HBc positivity), since this
status dictates the need for HBV treatment, prophylaxis, or
simple monitoring. In HBV patients with IBD, administration
of IFN is not recommended due to the potential risk of IBD
exacerbations and thanks to the availability of safe NUCs,
350management of HBV infection in IBD patients is performed
only with these latter drugs [52].
Active carriers are defined as HBsAg-positive, HBeAg- or anti-
 HBeAg-positive patients, with persistently or fluctuating ele-
vated aminotransferases and active viral replication (HBV-
355DNA > 2000 IU/ml): this condition, which is defined chronic
hepatitis, is associatedwith progressive liver disease and requires
HBV treatment independently from administration of immuno-
suppressive therapy for IBD. Third-generation NUCs Entecavir or
Tenofovir are the recommended drugs, due to the potent anti-
360viral activity, resulting in rapid viral suppression, and high barrier
to resistance [53]. As shown by registration trials and real-life
studies, these drugs achieve HBV-DNA negativity in more than
99% patients with none or negligible resistance rates long term
[54,55] and, consequently, have optimal profile also to manage
365long-term immunosuppressive treatments required for IBD.
Safety and efficacy of NUCs for treating HBV infection in IBD
patients have been confirmed in case series and study cohorts
[55]. Treatment duration in active carriers is dictated by the need
of treating HBV chronic hepatitis per se, independently from
370immunosuppressive therapy for IBD; at present, NUCs adminis-
tration is intended life long, although some studies are concen-
trating on the possibility to stop NUCs administration after many
years of efficient viral suppression or after achievement of HBsAg
negativity.
375Inactive carriers are defined as  HBsAg-positive, anti- HBe-
positive patients with persistently normal aminotransferases
and HBV-DNA < 2000 IU/ml: these patients have no evidence
of progressive liver disease and do not require antiviral treat-
ment in the HBV general population. On the contrary, as
380discussed above, risk of HBV reactivation in  HBsAg-positive
IBD patients undergoing immunosuppressive therapy ranges
from 20% to more than 30% and requires prophylaxis of HBV
reactivation by NUCs administration. Risk of HBV reactivation
depends on the type of immunosuppressive agent adminis-
385tered: anti-TNF drugs, integrin inhibitors, and a course of
prednisone ≤ 10 mg/day for at least 4 weeks are considered
at moderate risk, so that prophylaxis is mandatory [56]. There
has been much debate about the possibility of using a less
potent NUC like Lamivudine to prevent HBV reactivation in
390inactive carriers, who typically display low levels of HBV repli-
cation and, consequently, could be managed by a less expen-
sive drug than third-generation NUCs Entecavir and Tenofovir.
However, the prolonged administration of immunosuppres-
sion for IBD advises against using a drug with low barrier to
395resistance as Lamivudine, as some cases of resistance to
Lamivudine pr ophylaxis are described [33], so that today
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third-generation NUCs are the preferred drugs for prophylaxis
in HBV inactive carriers [52]. Absence of correct prophylaxis
strategies and use of weak drugs like Lamivudine could justify
400 bad outcomes reported by studies concentrating on HBV
reactivation in IBD patients in past years. HBV prophylaxis
should be carried on for the entire duration of immunosup-
pressive treatment and prolonged after the discontinuation of
immunosuppressants due to the fact that the risk of HBV
405 reactivation is higher when immune reconstitution occurs
[26,53,56,57]. There is currently much debate about the
recommended duration of HBV prophylaxis after discontinua-
tion of immunosuppressive therapy, as at least 6 –12 months
have been suggested, depending also on the type of immu-
410 nosuppressive agent administered [26,56].
To simplify and summarize management of HBsAg-positive
patients who need immunosuppressive treatment for concurrent
IBD, administration of third-generation NUCs Entecavir or
Tenofovir is recommended to treat HBV (active carriers) or as a
415 prophylaxis for HBV reactivation (inactive carriers); the duration
depends on HBV status, as active carriers need to be treated life
long, whereas prophylaxis in inactive carriers can be discontinued
6–12months after the cessation of immunosuppressive treatment.
 HBsAg-negative,  anti-HBc-positive patients efficiently
420 resolved HBV infection and do not display serological viral repli-
cation. However, HBV ccDNA can be found in hepatocytes and a
profound immunosuppression can result in restarting viral repli-
cation and HBsAg serum reappearance, the so-called serorever-
sion [26]. The highest risk of HBV seroreversion is found in onco-
425 hematologic setting, especially in case of potent CD20 B cell
antagonists (Rituximab), so that HBV prophylaxis is required. In
IBD patients, as well as in rheumatologic diseases, the level of
immunosuppression is lower and only isolated cases of serore-
version are described, so that guidelines recommend only peri-
430 odical (every 3–4months) monitoring of HBsAg and HBV-DNA, to
early detect potential seroreversion and start HBV treatment
promptly. The suggested NUC agents to treat seroreversion are
again third-generation NUCs Entecavir and Tenofovir, due to the
potent antiviral activity and fast virological suppression. This
435 strategy allows to quickly control HBV replication and should
be preferred to Lamivudine administration [26,53,55].
Anti-HBV vaccination is recommended in all IBD patients
with negative HBV serology: in patients receiving concurrent
treatment with immunosuppressants, the standard schedule
440for HBV vaccination has been shown ineffective in conferring
adequate seroprotection [58]. Importantly, adequate serologi-
cal response AQ4to anti-HBs vaccination has been recently
reported in healthy subjects exposed to the α4β7 integrin
inhibitor vedolizumab, as to suggest that the gut selectivity
445of this monoclonal antibody may be associated with reduced
immunosuppressive effects following exposure to parenteral
vaccines [59]. Nonetheless, an accelerated schedule AQ5with
 double-dose recombinant HBsAg (40 mcg at 0–1 2 months)
has been advocated as the best vaccination strategy for IBD
450patients: in the REPENTINA-3 multicenter study, administration
of accelerated  double-dose rHBsAg provided seroprotection
(anti-HBs title 10–100 mIU/mL) in 110/254 (43%) IBD patients
and effective vaccination ( anti-HBs > 100 mIU/mL) in 67/254
(27%) [60]. Another study in 241 IBD patients showed higher
455efficacy rates, respectively, 59% for seroprotection and 42% for
vaccination [61]. Serological response to vaccination should be
checked after 1 or 2 months, and revaccination is recom-
mended in patients failing to achieve adequate response
after a first vaccine course. As seroprotection loss can occur
460long term, regular monitoring of anti-HBs titles should be
performed yearly or every 2 years, and a unique booster
dose is recommended to restore anti-HBs title > 100 mIU/
mL, especially in patients undergoing anti-TNF treatment [52].
Given the relative safety of immunosuppressive drugs for
465IBD in HCV-infected patients, current recommendations do not
contraindicate immunomodulators in HCV patients, although
the decision should be based on the severity of both IBD and
liver disease. Regular monitoring of liver function tests and
aminotransferases every 3 months is suggested; no safety data
470exist about treatment of patients suffering from liver dysfunc-
tion with immunomodulators and especially anti-TNF drugs,
so that they are currently not recommended in decompen-
sated cirrhosis [52].
Current guidelines on management of HBV or HCV-infected
475IBD patients receiving immunosuppressive treatment are sum-
marized in Table 2.
Table 2. Recommendations for management of HBV or HCV-infected IBD patients receiving immunosuppressive treatment.
HBV
Before treatment All patients should be screened for HBV infection: HBsAg, anti-HBs, anti-HBc
In HBsAg+ patients → HBeAg, anti-HBe and HBV-DNA assessment
In patients with negativeAQ6 HBV markers → anti-HBV vaccination (rHBsAg 40 mcg 0–1 2 months)
Check serological response by anti-HBs dosing 1 or 2 months after vaccination
Monitor anti-HBs title every 2 years
HBV active carriers
HBsAg+, HBeAg+/anti-HBe+,
ALT↑, HBV-DNA++
Anti-HBV therapy with third-generation NUCs (Etecavir or Tenofovir)
Duration dictated by liver disease treatment
HBV inactive carriers
HBsAg+, anti-HBe+,
normal ALT, HBV-DNA < 2000 IU/ml
Prophylaxis with third-generation NUCs (Entecavir or Tenofovir)
To be administered until at least 6–12 months after discontinuation of immunosuppressive treatment
Previous HBV exposure
HBsAg −, anti-HBc+, anti-HBs±
Monitor HBsAg and HBV-DNA every 3–4 months
Start NUC treatment if evidence of seroreversion
HCV
Before treatment All patients should be screened for anti-HCV; in anti-HCV+ → HCV-RNA assessment
Administration of immunomodulators should be decided basing on liver disease severity
Anti-TNF drugs contraindicated in decompensated cirrhosis
During treatment Monitor liver tests every 3 months (ALT, ALP, GGT, bilirubin, albumin, platelets
NUC: nucleotide/nucleoside analog s; ALT: aminotransferases; ALP: alkaline phosphatase; GGT: γ-glutamil-transpeptidase
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In HCV patients, concurrent IBD represented in the past a
relative contraindication to IFN-based treatment due to the
risk of IBD exacerbation. This was true especially for CD, where
480 administration of IFN was associated with CD onset in pre-
viously asymptomatic patients [62,63] or exacerbations of
known CD, although an Austrian study on 11 CD patients
receiving PegIFN and Ribavirin treatment demonstrated that,
in 6 patients exhibiting CD reactivation, the disease could be
485 efficiently managed by optimizing immunosuppressive treat-
ment with steroids [64]. In addition, antiviral treatment in CD
patients showed comparable efficacy with respect to the gen-
eral HCV population. On the other hand, IFN had been initially
claimed as a potential adjuvant treatment to induce UC remis-
490 sion, however a randomized-controlled trial in 60 UC patients
failed to confirm this hypothesis, although it demonstrated
that PegIFN administration in UC patients did not translate
in increased adverse events [65]. A review of existing literature
concluded that IFN-based treatment could be feasible in
495 patients with stable IBD remission [66].
This notwithstanding, the recent development of direct-
acting antiviral drugs (DAAs) to cure HCV infection paved the
way to safely achieve viral eradication in IBD patients. Indeed,
the elimination of IFN from the recommended standard of
500 care treatment has allowed to extend eligibility to antiviral
therapy also in patients suffering from immune-mediated dis-
eases like IBD [67]. While efficacy of DAAs in registration trials
and real-life studies exceeds 95% across nearly all genotypes
in the HCV general population, more data are currently
505 needed in special populations like IBD patients, although
there is no theoretical reason to suspect a reduced DAAs
efficacy in this patient population. Concerning safety, the
only topic to address are the potential DDIs between DAAs
and immunosuppressive drugs, especially anti-TNF.
510 5. Drug–drug interactions
A pharmacokinetic drug interaction occurs when one drug
(perpetrator) alters the concentrations of a second drug (vic-
tim). Pharmacokinetic interactions at the level of drug meta-
bolism represent an important site for DDIs. Cytochrome P450
515 iso enzymes are responsible for the metabolism of many drugs.
In particular, CYP3A is responsible for the oxidative metabo-
lism of more than 40% of the drugs in clinical use [68]. Many
DDIs are attributable to CYP450 enzyme inhibition or induc-
tion. There are limited pharmacokinetic DDI studies between
520 HCV DAA and drugs used in the treatment of IBD. An under-
standing of drug disposition for drugs used in the treatment
of IBD can guide in predicting potential DDIs in the absence of
pharmacokinetic interaction studies. Steroids are frequently
used systemically or topically in inducing remission in IBD.
525 Systemic absorption of steroids may occur with topical rectal
suppositories or foam enemas, but is rarely complete.
Prednisolone, the active metabolite of prednisone is formed
in vivo by 11β-hydroxydehydrogenase after oral administra-
tion. Prednisolone is subsequently metabolize d through a
530  CYP3A4-mediated pathway [69]. Drugs that inhibit CYP3A
will result in increased systemic exposure of prednisolone,
with an increased risk of  steroid-related side effects.
Prednisone is also a substrate of P-glycoprotein (P-gp) [70,71].
Azathioprine is the pro drug of 6-mercaptopurine, which is
535further metabolize d to natural purines by inosine monopho-
sphate dehydrogenase (IMPDH) [72]. Methotrexate is a sub-
strate of the OATP1B1 and breast cancer resistance protein
(BCRP) drug transporters, and is predominantly eliminated
unchanged by the kidneys with minimal metabolism [73,74].
540Inhibitors of the OATP1B1 or BCRP drug transporters may
therefore increase methotrexate concentrations with potential
toxicity.
5.1. Ledipasvir–sofosbuvir
Ledipasvir (90 mg) and sofosbuvir (400 mg) are co-formulated
545in a fixed dose combination that is administered once daily.
Neither sofosbuvir nor ledipasvir are metabolize d by CYP450
enzymes. Ledipasvir is primarily excreted in bile as unchanged
part drug. Sofosbuvir is a P-gp substrate, and ledipasvir is a
weak inhibitor of P-gp and BCRP [75]. Co administration of
550ledipasvir–sofosbuvir has not been studie d with prednisone,
azathioprine, or methotrexate. However, a clinically significant
interaction with prednisolone azathioprine/6-mercaptopurine,
or methotrexate is unlikely based on their metabolic
pathways.
5555.2. Simeprevir–sofosbuvir
Simeprevir (an NS4/4A protease inhibitor) is metabolize d by
CYP3A and is a mild inhibitor of intestinal CYP3A and CYP1A2
[76]. No interaction is expected between simeprevir and
azathioprine (6-mercaptopurine) or methotrexate.
560Co administration of simeprevir with prednisone may result in
increased systemic exposure of prednisolone due to inhibition
of intestinal CYP3A4 be simeprevir. While no dose adjustment
of prednisone is required, monitoring for steroid side effects is
recommended.
5655.3. Daclatasvir–sofosbuvir
Daclatsavir (an NS5A inhibitor) is a substrate of CYP3A4 and
P-gp, and an inhibitor of OATP1B1, P-gp and BCRP [77]. While
co administration has not been studied, no clinically significant
interaction is expected between daclatasvir and azathioprine
570(6-mercaptopurine) or prednisone. A potential interaction
exists between daclatasvir and methotrexate. The administra-
tion of daclatasvir in a patient receiving methotrexate may
result in increased concentrations of methotrexate due to
daclatasvir-mediated inhibition of the OATP1B1 drug transpor-
575ter. H ematological blood monitoring is required with this
combination.
5.4. Ritonavir-boosted paritaprevir, ombitasvir plus
dasabuvir (P/r/O + D)
Paritaprevir is metabolize d by CYP3A and is given with low-
580dose ritonavir, a potent CYP3A inhibitor to optimize paritapre-
vir exposure. This combination has the potential for numerous
 ritonavir-related DDIs. Ritonavir is a potent hepatic and intest-
inal CYP3A inhibitor, and also inhibits P-gp and BCRP.
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Paritaprevir is an inhibitor of OATP-1B1/1B3, P-gp and BCRP.
585 Dasabuvir is an inhibitor of BCRP and P-gp [78–82].
There is no overlap in the metabolic pathways of P/r/O + D
and azathioprine/6-mercaptopurine. Therefore, no drug inter-
actions are expected. Monitoring of h ematological blood
counts would be prudent if P/r/O + D is administered with
590 methotrexate due to BCRP inhibition by ritanovir, paritaprevir,
and dasabuvir. Co administration of P/r/O + D with prednisone
has not been studied. Prednisolone exposure may be
increased due to CYP3A4 inhibition by ritonavir. Patients
should be monitored for steroid-related side effects.
595 5.5. Grazoprevir–elbasvir
The Food and Drug Administration (FDA) in the United States
has recently approved the combination of grazoprevir and
elbasvir for the treatment of HCV [83]. Grazoprevir and elbasvir
inhibit BCRP, while elbasvir also inhibits P-gp [84].
600 Methotrexate levels may be increased in the presence of
grazoprevir–elbasvir as a result of BCRP inhibition. Patients
should be carefully monitored if this combination is used
with methotrexate. No interactions are expected with
azathioprine/6-mercaptopurine or prednisone.
605 5.6. Ribavirin
Ribavirin is frequently administered in combination with HCV
DAA in patients with cirrhosis or previous treatment experi-
ence to maximize response to therapy, and shorten treatment
duration [85]. A significant potential interaction exists with
610 ribavirin and azathioprine (6-mercaptopurine). Ribavirin has
an inhibitory effect on IMPDH [86], an important enzyme in
the metabolic pathway of 6-mercaptopurine. The
co administration of ribavirin with azathioprine or 6-merpato-
purine may result in elevated levels of 6-methylthioinosine
615 monophosphate (6-MTITP) through blockade of IMPDH activ-
ity [87]. Elevated levels of 6-MTITP have been shown to be
associated with myelotoxicity (neutropenia, thrombocytopenia
and/or an emia) in patients treated with azathioprine for IBD
[72]. Pancytopenia and bone marrow suppression have been
620 reported in eight patients receiving pegylated IFN ribavirin
concomitantly with azathioprine [87]. The combination of
ribavirin with azathioprine is contraindicated in patients with
high thiopurine methyltransferase (TPMT) levels, and should
also ideally be avoided in patients with normal TPMT activity
625 given the risk of myelotoxicity [87]. This potential interaction
exists for up to 2 months after the cessation of ribavirin
therapy because of its long half-life.
5.7. Biologics for IBD
Biologics including anti-TNF-α antibodies (e.g. infliximab, adali-
630 mumab) and anti-integrins (e.g. vedolizumab) have
revolutionize d the management of IBD. Infliximab and vedolizu-
mab are given as an intravenous infusion, whereas adalimumab
is administered via subcutaneous injection. The elimination
pathways for these agents have not been characterize d and
635 no drug interaction studies have been performed between
HCV DAA and biologic agents for IBD. Clinically significant
interactions would not however be expected as the biologics
are not substrates of CYP450 and gut transporters.
5.8. Nucleoside analog s for hepatitis B
640Nucleoside analog s have an excellent safety profile in patients
with hepatitis B, including those with decompensated cirrhosis
[88]. However, given the low rate of HBsAg seroconversion
seen with these agents, prolonged therapy is frequently
required [89]. Lamivudine and entecavir are predominantly
645excreted unchanged in the urine [90,91]. The kidneys primarily
excrete tenofovir DF by both tubular filtration and active
tubular secretion [92]. There is a potential for competitive
inhibition for active tubular secretion if lamivudine and meth-
otrexate are co-prescribed, which may result in increased
650serum concentrations of either or both drugs with associated
potential toxicity. This competitive inhibition for renal tubular
secretion may also arise with tenofovir DF and methotrexate.
This combination would require close monitoring of renal
function.
655Main DDIs between HBV/HCV DAAs and IBD agents are
summarized in Table 3.
6. Expert commentary
IBD (CD and UC) are chronic diseases affecting the intestinal
tract, characterized also by a systemic involvement due to
660extraintestinal manifestations. The natural course of IBD typi-
cally alternates periods of disease remission and
recrudescence with reactivations displaying different degrees
of severity, potentially resulting in need for surgical treatment.
The long course of the disease, the specific bowel involvement
665resulting in discomforting symptoms, and the severe exacer-
bations requiring hospitalization and surgery determine a
strong impairment in patients’ quality of life, in terms of social,
working, and also relational disability.
At present, management of these patients is complicated
670by a limited knowledge of precise causative and pathophysio-
logical mechanisms, so that current treatment strategy
requires administration of immunosuppressing/immunomo-
dulating drugs in order to achieve and maintain disease remis-
sion. These drugs require careful and specialist management
675because they are characterized by side effects both short term
(i.e. steroid-induced diabetes) and long term (i.e. increased risk
of malignancies), so that periodical monitoring is recom-
mended and, in some cases, treatment is supplied only in
hospital settings. In this scenario, patient comorbidities and
680concomitant diseases have to be carefully considered before
starting immunosuppressive treatments: as chronic infection
with HBV or HCV affect, respectively, more than 400 and 150
million people worldwide, these liver diseases are likely to
interplay with IBD according to local epidemiology in different
685countries.
Due to the potential risk of hepatitis reactivation during
immunosuppressing therapy, current management of IBD
patients requires screening for HBV and HCV markers before
starting immunosuppressive treatment, in order to determine
690the patient’s virological status and consequently the need for
treating chronic hepatitis or administering adequate
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prophylaxis to prevent hepatitis reactivation in the HBV set-
ting. As a consequence, this strategy is actually complex 
because it presumes good knowledge of different hepatitis
695 serological markers and specialist referral for HBV/HCV treat-
ment administration or monitoring.
However, research in the field of viral hepatitis is pushing
very hard and the recent development of new DAA s has
paved the way for a true revolution in HCV treatment, due
700 to the high efficacy rates and, most of all, the excellent safety
profile allowing to treat patients formerly contraindicated to
antiviral therapy in the IFN-based era. This is particularly
appealing for IBD patients, as risk for IBD reactivation with
IFN excluded many patients from the possibility to receive
705 HCV therapy in the past. If widespread of DAAs will be pursed
at the global level, HCV eradication will be feasible in the next
decades, so that concurrent HCV infection will no longer
represent a clinical problem in IBD management. In the HBV
setting, on the other hand, current nucleotide/nucleoside ana-
710 log s are already efficacious and safe, however they achieve
only virological suppression and due to the specific HBV repli-
cation cycle, are not able to eradicate the virus (the so-called
 functional cure ). This is the specific research area in the HBV
field at the moment, where new compounds are intended to
715 target the cccDNA replication machinery, that is also the driv-
ing force of viral reactivation during immunosuppressive treat-
ment. If the functional cure will be achieved, also HBV will not
impact IBD clinical management so far. Finally, the most
important research area in the near future will be the devel-
720opment of new compounds for IBD therapy with the primary
goal of achieving remission in patients failing to respond to
currently available treatment options. Another primary goal
will be to develop IBD drugs targeting different molecular
pathways, in order to provide safer and manageable com-
725pounds with reduced need for monitoring and fewer side
effects. These goals will be achieved only through a deeper
insight in pathophysiological mechanisms of IBD that should
be pursued by strong effort in basic research.
7. Conclusions and 5-year view
730The current management of patients with chronic HBV or HCV
and concomitant IBD requires precise definition of the viral
disease status, viral replication levels, and disease stage.
Internationally accepted guidelines which have been summar-
ized in this paper provide an adequate tool to manage the risk
735of HBV reactivation, HBsAg seroconversion, and concomitant
chronic HCV infection. In the upcoming years, novel therapeu-
tic strategies will be included into the therapeutic armamen-
tarium for patients with active IBD [93]. Among these, it is
presumable that a low risk of HBV or HCV reactivation will be
740observed following administration of compounds with gut-
selective mechanisms of action (e.g. α4β7 integrin inhibitors)
Table 3. Specific drug-drug interactions between HBV/HCV DAA and IBD agents.
Prednisolone Azathioprine/6-MP Methotrexate
Sofosbuvir–ledipasvir No interaction expected No interaction expected No interaction expected
Sofosbuvir–simeprevir Potential for increased prednisolone
concentrations due to simeprevir
intestinal CYP3A inhibition;
monitor for steroid side effects
No interaction expected No interaction expected
Sofosbuvir–daclatasvir No interaction expected No interaction expected Potential for increased methotrexate
concentrations due to daclatasvir
inhibition of OATP1B1;
h ematological monitoring required
Paritaprevir/ritonavir
Ombitasvir
Dasabuvir
Prednisolone exposure may be
increased due to ritonavir CYP3A4
inhibition;
monitor for steroid side effects
No interaction expected Interaction not studied; no
interaction expected, but
h ematological monitoring should
be considered
Grazoprevir–elbasvir No interaction expected No interaction expected Methotrexate concentrations may be
increased due to BCRP & P-gp
inhibition; Careful h ematological
monitoring is required
Ribavirin No clear data May result in elevated levels of 6-MTITP
due to IMPDH inhibition with risk of
myelotoxicity;
co administration contraindicated in
patients with high TMPT levels and
should be avoided in patients in
normal TMPT levels
No pharmacokinetic interaction; this
combination may result in an emia
Tenofovir–DF No clear data No interaction expected Potential for increased serum
concentrations of methotrexate
and tenofovir due to competitive
for active renal tubular secretion;
renal monitoring required
Lamivudine No clear data No interaction expected Potential for increased serum
concentrations of methotrexate
and lamivudine due to
competitive for active renal
tubular secretion;
renal monitoring required
6-MP: 6-mercaptopurine; CYP3A:  cytochrome P3A4; OATP1B1: organic anion-transporting polypeptide 1B1; BCRP: breast cancer resistance protein; P-gp:
P-glycoprotein; MTITP: methylthioinosine monophosphate; IMPDH: inosine monophosphate dehydrogenase; TPMT: thiopurine methyltransferase
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or with negligible systemic absorption, (SMAD7 antisense inhi-
bitors). On the contrary, further data are urgently needed to
evaluate hepatic toxicity of a novel generation of immunosup-
745 pressive drugs for IBD, including JAK inhibitors and anti-IL12/
23 monoclonal antibodies, which could potentially interfere
with immunological surveillance of hepatotropic viruses.
Similarly, further therapeutic advances are expected to enter
the HBV and HCV field. For the treatment of HCV, next-gen-
750 eration DAAs will be optimized versions of currently available
drugs, with pan-genotypic activity, optimal pharmacokinetic
profile and high genetic barrier to resistance that will allow
these drugs to be active also in treatment failures to first- and
 second-generation DAAs. Although it will be mandatory to
755 asses DDIs with these new compounds, the management of
viral hepatitis C in patients with IBD is unlikely to be modified
by these DAAs. On the other hand, treatment of HBV will be
radically transformed in the next years by drugs that target the
immune system as well as antivirals that inhibit different steps
760 of the HBV life cycle including modulation and silencing of
ccc-DNA transcription. These drugs could solve the need for
active prophylaxis of patients receiving immunosuppressive
drugs and thus could play a major role in the management
of HBV in patients with IBD.
765 Key issues
● Prevalence of HBV and HCV infections in IBD patients is the
same as the general population, according to the local
epidemiology of hepatitis infections.
● IBD prevalence and incidence is on the rise both in Western
770 and Eastern countries.
● In HBV infection, immunosuppressive treatments carry an
increased risk of hepatitis reactivation, depending on the
patient’s serological status (active carrier, inactive carrier or
resolved HBV infection).
775 ● HBV active carriers need to be treated for chronic hepatitis
with NUC-based therapy, independently from administra-
tion of immunosuppressive treatment.
● HBV inactive carriers should receive NUC-based prophylaxis
for hepatitis reactivation, to be continued until at least
780 12 months after cessation of immunosuppressive
treatment.
● Patients with markers of previous HBV exposure need to be
monitored every 3–4 months in order to detect potential
seroreversion.
785 ● Anti-HBV vaccination with double-dose accelerated sche-
dule should be administered to all IBD patients with nega-
tive HBV markers before starting immunosuppressive
treatment.
● In HCV patients, administration of immunosuppressive treat-
790 ment should be decided basing on liver disease severity (anti-
TNF are contraindicated in decompensated cirrhosis) and
periodical monitoring of liver function tests is required.
● Careful check of drug-drug interactions between immuno-
suppressive regimens and HBV/HCV drugs is required
795 before starting treatment.
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